Evidence map›Paper›PMID 36597912›Full record

ArticleJournal of medical virology2023

Integrative systems immunology uncovers molecular networks of the cell cycle that stratify COVID-19 severity.

Caroline Aliane de Souza Prado, Dennyson Leandro M Fonseca, Youvika Singh, Igor Salerno Filgueiras, Gabriela Crispim Baiocchi, Desirée Rodrigues Plaça, Alexandre H C Marques, Raquel Costa Silva Dantas-Komatsu, Júlia N Usuda, Paula Paccielli Freire and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 8 countries.

Caroline Aliane de Souza PradoDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Dennyson Leandro M FonsecaInterunit Postgraduate Program on Bioinformatics, Institute of Mathematics and Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil.
Youvika SinghDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Igor Salerno FilgueirasDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Gabriela Crispim BaiocchiDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Desirée Rodrigues PlaçaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-0305-8289
Alexandre H C MarquesDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Raquel Costa Silva Dantas-KomatsuPostgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil.
Júlia N UsudaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Paula Paccielli FreireDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Ranieri Coelho SalgadoDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Sarah Maria da Silva NapoleaoDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Rodrigo Nalio RamosLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Departament of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil.
Vanderson RochaLaboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Departament of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil.
Guangyan ZhouInstitute of Parasitology, McGill University, Montreal, Quebec, Canada.
Rusan CatarDepartment of Nephrology and Internal Intensive Care Medicine, Charité University Hospital, Berlin, Germany.
Guido MollDepartment of Nephrology and Internal Intensive Care Medicine, Charité University Hospital, Berlin, Germany.
Niels Olsen Saraiva CamaraDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Gustavo Cabral de MirandaDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Vera Lúcia Garcia CalichDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Lasse M GiilDepartment of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
Neha MishraInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Florian TranInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Andre Ducati LuchessiDepartment of Clinical and Toxicology Analysis, Federal University of Rio Grande do Norte, Natal, Brazil.
Helder I NakayaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Hans D OchsDepartment of Pediatrics, University of Washington School of Medicine and Seattle Children's Research Institute, Seattle, Washington, USA.
Igor JurisicaOsteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, UHN, Toronto, Ontario, Canada.
Lena F SchimkeDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Otavio Cabral-MarquesDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-3183-6236
Universidade de São Paulo · BRHochschule für Angewandte Wissenschaften Kiel · DEUniversidade Federal do Rio Grande do Norte · BRCharité - Universitätsmedizin Berlin · DEDeaconess Hospital · USD’Or Institute for Research and Education · BRHumboldt-Universität zu Berlin · DEInstitute of Parasitology of the Slovak Academy of Sciences · SKSeattle Children's Hospital · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several perturbations in the number of peripheral blood leukocytes, such as neutrophilia and lymphopenia associated with Coronavirus disease 2019 (COVID-19) severity, point to systemic molecular cell cycle alterations during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. However, the landscape of cell cycle alterations in COVID-19 remains primarily unexplored. Here, we performed an integrative systems immunology analysis of publicly available proteome and transcriptome data to characterize global changes in the cell cycle signature of COVID-19 patients. We found significantly enriched cell cycle-associated gene co-expression modules and an interconnected network of cell cycle-associated differentially expressed proteins (DEPs) and genes (DEGs) by integrating the molecular data of 1469 individuals (981 SARS-CoV-2 infected patients and 488 controls [either healthy controls or individuals with other respiratory illnesses]). Among these DEPs and DEGs are several cyclins, cell division cycles, cyclin-dependent kinases, and mini-chromosome maintenance proteins. COVID-19 patients partially shared the expression pattern of some cell cycle-associated genes with other respiratory illnesses but exhibited some specific differential features. Notably, the cell cycle signature predominated in the patients' blood leukocytes (B, T, and natural killer cells) and was associated with COVID-19 severity and disease trajectories. These results provide a unique global understanding of distinct alterations in cell cycle-associated molecules in COVID-19 patients, suggesting new putative pathways for therapeutic intervention.

Indexed as

COVID-19Cell CycleHumansKiller Cells, NaturalSARS-CoV-2Transcriptomecell cycle associated moleculesCOVID-19 severityproteomicsSARS-CoV-2systems immunologytranscriptomics

Identifiers

PMID36597912
PMCPMC10107240
OpenAlexW4313488786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.